<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644614003559</prism:url><dc:identifier>doi:10.1016/j.drudis.2014.09.006</dc:identifier><eid>1-s2.0-S1359644614003559</eid><prism:doi>10.1016/j.drudis.2014.09.006</prism:doi><pii>S1359-6446(14)00355-9</pii><dc:title>Microbial amphiphiles: a class of promising new-generation anticancer agents </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><prism:volume>20</prism:volume><prism:issueIdentifier>1</prism:issueidentifier><prism:startingPage>136</prism:startingpage><prism:endingPage>146</prism:endingpage><prism:pageRange>136-146</prism:pagerange><prism:number>1</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2015-01-31</prism:coverdate><prism:coverDisplayDate>January 2015</prism:coverdisplaydate><prism:copyright>Copyright © 2014 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Dey, Goutam</dc:creator><dc:creator>Bharti, Rashmi</dc:creator><dc:creator>Sen, Ramkrishna</dc:creator><dc:creator>Mandal, Mahitosh</dc:creator><dc:description>
                  Developing new classes of anticancer molecules has always been a major scientific challenge owing to multidrug resistance of cancer cells to conventional chemotherapeutic agents. Microbial amphiphiles, particularly lipopeptides and glycolipids, have recently emerged as potential new-generation anticancer agents, owing to low toxicity, high efficacy and easy biodegradability. They exhibit anticancer activities by retarding cell cycle progression, inhibiting crucial signaling pathways such as Akt, extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) and Janus kinase/signal transducer and activator of transcription (JAK/STAT), reducing angiogenesis, activating natural killer T (NKT) cells and inducing apoptosis through death receptors in cancer cells. It has been well established that the oncogenic signals of cancer cells are amplified by the overexpression of various membrane-bound receptors such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and insulin-like growth factor receptor (IGFR). Microbial amphiphiles, upon interaction with the cell membrane, are believed to suppress the activities of these cell surface receptors by fatty acid chain mediated membrane destabilization. This review analyzes the modes and mechanisms of action of these green molecules for application as potential anticancer agents.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644614003559" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644614003559" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="141" size="12991">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="160" size="12143">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="187" height="164" size="13295">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="164" size="13823">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="134" size="13104">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="19885">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="151" size="18050">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="21051">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="187" height="164" size="14639">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="95" size="10148">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="10308">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="9774">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="152" size="12838">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="85" size="8489">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="132" size="11399">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="8160">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="93" size="11248">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="181" height="164" size="14758">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="15070">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="115" size="8792">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="310" height="200" size="22305">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="207" height="151" size="22836">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="234" height="205" size="28279">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="248" height="186" size="27527">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="215" height="132" size="23787">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="240" height="193" size="40064">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="222" height="154" size="33122">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="241" size="46499">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="244" height="214" size="30821">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="249" height="108" size="20538">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="234" height="131" size="21192">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="245" height="138" size="19369">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="241" height="167" size="26616">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="251" height="98" size="16886">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="211" height="127" size="21445">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="237" height="109" size="16205">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="92" size="21049">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="189" height="171" size="27222">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="419" size="103686">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="439" size="67424">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1376" height="886" size="169086">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="917" height="669" size="69471">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1037" height="909" size="92596">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1100" height="825" size="96751">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="952" height="584" size="71749">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1064" height="857" size="128635">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="986" height="682" size="91658">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1113" height="1068" size="154691">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1084" height="952" size="105067">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1102" height="476" size="59459">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1036" height="579" size="64860">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1085" height="612" size="65014">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1070" height="741" size="95559">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1114" height="433" size="53788">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="937" height="564" size="71884">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1052" height="483" size="46794">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="958" height="407" size="66599">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="838" height="760" size="79324">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1856" size="914923">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="1943" size="551921">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644614003559-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>84922463321</scopus-id><scopus-eid>2-s2.0-84922463321</scopus-eid><pubmed-id>25241656</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84922463321" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20140919">2014-09-19</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20140919">2014-09-19</xocs:available-online-date>
      <xocs:ew-transaction-id>2016-02-20T00:59:57</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644614003559</xocs:eid>
      <xocs:pii-formatted>S1359-6446(14)00355-9</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644614003559</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2014.09.006</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644615X0002X</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20160219">2016-02-19T20:21:31.08164-05:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20150101</xocs:date-search-begin>
      <xocs:date-search-end>20150131</xocs:date-search-end>
      <xocs:year-nav>2015</xocs:year-nav>
      <xocs:indexeddate epoch="1411143729">2014-09-19T16:22:09.470651Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authlast grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>20</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>20</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>1</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>1</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 20, Issue 1</xocs:vol-iss-suppl-text>
      <xocs:sort-order>18</xocs:sort-order>
      <xocs:first-fp>136</xocs:first-fp>
      <xocs:last-lp>146</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>136</xocs:first-page>
         <xocs:last-page>146</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>201501</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>January 2015</xocs:cover-date-text>
      <xocs:cover-date-start>2015-01-01</xocs:cover-date-start>
      <xocs:cover-date-end>2015-01-31</xocs:cover-date-end>
      <xocs:cover-date-year>2015</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Reviews</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Post Screen</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Copyright © 2014 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>MICROBIALAMPHIPHILESACLASSPROMISINGNEWGENERATIONANTICANCERAGENTS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>DEY</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>G</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Types of amphiphiles and their anticancer properties</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Structure–function relation of microbial amphiphiles</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Lipopeptides</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Surfactin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Iturin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Fengycin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Somocystinamide A</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Fellutamides</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Pseudofactin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Rakicidin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Apratoxin</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Glycolipids</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Other glycolipids</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks and future perspectives</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>CRAGG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>72</xocs:ref-first-fp>
            <xocs:ref-last-lp>79</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>HOLLSTEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1974</xocs:ref-pub-year>
            <xocs:ref-first-fp>625</xocs:ref-first-fp>
            <xocs:ref-last-lp>652</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>NIRAULA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1187</xocs:ref-first-fp>
            <xocs:ref-last-lp>1194</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>GUDINA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>667</xocs:ref-first-fp>
            <xocs:ref-last-lp>675</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>215</xocs:ref-first-fp>
            <xocs:ref-last-lp>222</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>WRASIDLO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2313</xocs:ref-first-fp>
            <xocs:ref-last-lp>2318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>DAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>e46641</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>RAJPUT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e61342</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>CAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>357</xocs:ref-first-fp>
            <xocs:ref-last-lp>362</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>91</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>287</xocs:ref-first-fp>
            <xocs:ref-last-lp>296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>MUKHERJEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>509</xocs:ref-first-fp>
            <xocs:ref-last-lp>515</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2884</xocs:ref-first-fp>
            <xocs:ref-last-lp>2887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>794</xocs:ref-first-fp>
            <xocs:ref-last-lp>799</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>RANGARAJAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1661</xocs:ref-first-fp>
            <xocs:ref-last-lp>1669</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>719</xocs:ref-first-fp>
            <xocs:ref-last-lp>726</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>584</xocs:ref-first-fp>
            <xocs:ref-last-lp>594</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>HWANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>166</xocs:ref-first-fp>
            <xocs:ref-last-lp>171</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>ORTIZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>46</xocs:ref-first-fp>
            <xocs:ref-last-lp>53</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>MAGETDANA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>1937</xocs:ref-first-fp>
            <xocs:ref-last-lp>1943</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>GONZALEZASEGUINOLAZA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>8461</xocs:ref-first-fp>
            <xocs:ref-last-lp>8466</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>VANITTANAKOM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1986</xocs:ref-pub-year>
            <xocs:ref-first-fp>888</xocs:ref-first-fp>
            <xocs:ref-last-lp>901</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>SCHNEEKLOTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3855</xocs:ref-first-fp>
            <xocs:ref-last-lp>3858</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>7615</xocs:ref-first-fp>
            <xocs:ref-last-lp>7626</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>MORITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>2176</xocs:ref-first-fp>
            <xocs:ref-last-lp>2187</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>ISODA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>403</xocs:ref-first-fp>
            <xocs:ref-last-lp>406</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>39903</xocs:ref-first-fp>
            <xocs:ref-last-lp>39910</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>SHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>286</xocs:ref-first-fp>
            <xocs:ref-last-lp>291</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>SUDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>259</xocs:ref-first-fp>
            <xocs:ref-last-lp>264</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>79</xocs:ref-first-fp>
            <xocs:ref-last-lp>85</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>SIVAPATHASEKARAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>845</xocs:ref-first-fp>
            <xocs:ref-last-lp>854</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>SEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>316</xocs:ref-first-fp>
            <xocs:ref-last-lp>323</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>STELLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>11331</xocs:ref-first-fp>
            <xocs:ref-last-lp>11343</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>KAMEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1974</xocs:ref-pub-year>
            <xocs:ref-first-fp>938</xocs:ref-first-fp>
            <xocs:ref-last-lp>944</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>CAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>106</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>CAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>163</xocs:ref-first-fp>
            <xocs:ref-last-lp>171</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>865</xocs:ref-first-fp>
            <xocs:ref-last-lp>871</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1347</xocs:ref-first-fp>
            <xocs:ref-last-lp>1354</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>955</xocs:ref-first-fp>
            <xocs:ref-last-lp>963</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>NASIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>187</xocs:ref-first-fp>
            <xocs:ref-last-lp>193</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>TRISCHMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>5571</xocs:ref-first-fp>
            <xocs:ref-last-lp>5574</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1029</xocs:ref-first-fp>
            <xocs:ref-last-lp>1030</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>SUYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4449</xocs:ref-first-fp>
            <xocs:ref-last-lp>4452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3817</xocs:ref-first-fp>
            <xocs:ref-last-lp>3820</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>SHIGEMORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>8529</xocs:ref-first-fp>
            <xocs:ref-last-lp>8534</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>205</xocs:ref-first-fp>
            <xocs:ref-last-lp>208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1721</xocs:ref-first-fp>
            <xocs:ref-last-lp>1730</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>JANEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e57991</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>TAKEUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>591</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>759</xocs:ref-first-fp>
            <xocs:ref-last-lp>763</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>YAMAZAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>WILSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-last-lp>410</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>POULSEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>12837</xocs:ref-first-fp>
            <xocs:ref-last-lp>12839</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>NUNNERY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>787</xocs:ref-first-fp>
            <xocs:ref-last-lp>793</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>THORNBURG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1781</xocs:ref-first-fp>
            <xocs:ref-last-lp>1788</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>ROBERTSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>5192</xocs:ref-first-fp>
            <xocs:ref-last-lp>5195</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>TIDGEWELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1458</xocs:ref-first-fp>
            <xocs:ref-last-lp>1466</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>861</xocs:ref-first-fp>
            <xocs:ref-last-lp>865</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>KARANTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>116</xocs:ref-first-fp>
            <xocs:ref-last-lp>126</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>FUJI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>3380</xocs:ref-first-fp>
            <xocs:ref-last-lp>3387</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>NAKUI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>147</xocs:ref-first-fp>
            <xocs:ref-last-lp>153</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>HAYAKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1720</xocs:ref-first-fp>
            <xocs:ref-last-lp>1727</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>SCHNEIDERS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>130</xocs:ref-first-fp>
            <xocs:ref-last-lp>141</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>ISHIKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1910</xocs:ref-first-fp>
            <xocs:ref-last-lp>1917</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>GIACCONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>3702</xocs:ref-first-fp>
            <xocs:ref-last-lp>3709</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>YAMASAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>255</xocs:ref-first-fp>
            <xocs:ref-last-lp>265</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>NIEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>383</xocs:ref-first-fp>
            <xocs:ref-last-lp>389</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>KUNII</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1092</xocs:ref-first-fp>
            <xocs:ref-last-lp>1098</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0345">
            <xocs:ref-normalized-surname>MAEDA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>216</xocs:ref-first-fp>
            <xocs:ref-last-lp>223</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0350">
            <xocs:ref-normalized-surname>FAROKHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>406</xocs:ref-first-fp>
            <xocs:ref-last-lp>410</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0355">
            <xocs:ref-normalized-surname>MORITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>305</xocs:ref-first-fp>
            <xocs:ref-last-lp>313</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0360">
            <xocs:ref-normalized-surname>KITAMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>187</xocs:ref-first-fp>
            <xocs:ref-last-lp>201</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0365">
            <xocs:ref-normalized-surname>ISODA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>191</xocs:ref-first-fp>
            <xocs:ref-last-lp>195</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0370">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>482</xocs:ref-first-fp>
            <xocs:ref-last-lp>486</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0375">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>77</xocs:ref-first-fp>
            <xocs:ref-last-lp>82</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>DEYX2015X136</xocs:refkey3>
         <xocs:refkey4lp>DEYX2015X136X146</xocs:refkey4lp>
         <xocs:refkey4ai>DEYX2015X136XG</xocs:refkey4ai>
         <xocs:refkey5>DEYX2015X136X146XG</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(14)00355-9</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644614003559</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644614003559</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2014.09.006</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2016-02-19T20:21:31.08164-05:00</xocs:timestamp>
         <xocs:cover-date-start>2015-01-01</xocs:cover-date-start>
         <xocs:cover-date-end>2015-01-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/MAIN/application/pdf/8ed3639883e58a60294dd2f0ec807292/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/MAIN/application/pdf/8ed3639883e58a60294dd2f0ec807292/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1820698</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644614003559-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/PREVIEW/image/png/6c4e58b33573c4f82d883a4b9e0fdee7/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/PREVIEW/image/png/6c4e58b33573c4f82d883a4b9e0fdee7/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>94470</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx1/THUMBNAIL/image/gif/14eb37b2cf151df3a7b8b8f76c88d542/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx1/THUMBNAIL/image/gif/14eb37b2cf151df3a7b8b8f76c88d542/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12991</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx10/THUMBNAIL/image/gif/9b4b7f9995be46a0c2c1035e9db7fe71/fx10.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx10/THUMBNAIL/image/gif/9b4b7f9995be46a0c2c1035e9db7fe71/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12143</xocs:filesize>
               <xocs:pixel-height>160</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx11/THUMBNAIL/image/gif/71ebdaf3a1a610dcc0b483f2a7ea7e7b/fx11.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx11/THUMBNAIL/image/gif/71ebdaf3a1a610dcc0b483f2a7ea7e7b/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13295</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>187</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx12/THUMBNAIL/image/gif/26088de9fc998fbdc03b75e33ee9a047/fx12.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx12/THUMBNAIL/image/gif/26088de9fc998fbdc03b75e33ee9a047/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13823</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx13/THUMBNAIL/image/gif/fbd3b4c3883a87dd583754e9f1113cfd/fx13.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx13/THUMBNAIL/image/gif/fbd3b4c3883a87dd583754e9f1113cfd/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13104</xocs:filesize>
               <xocs:pixel-height>134</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx14/THUMBNAIL/image/gif/c6ed197565c1aff701545ac81b5121b1/fx14.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx14/THUMBNAIL/image/gif/c6ed197565c1aff701545ac81b5121b1/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19885</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx15/THUMBNAIL/image/gif/6517dc477e6f6a48f566e37c8f703d9e/fx15.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx15/THUMBNAIL/image/gif/6517dc477e6f6a48f566e37c8f703d9e/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>18050</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx16/THUMBNAIL/image/gif/902ab8ca0b135cc092ca668932f63090/fx16.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx16/THUMBNAIL/image/gif/902ab8ca0b135cc092ca668932f63090/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>21051</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx17/THUMBNAIL/image/gif/1feb17e95f3a7e7ecf70f638977aca50/fx17.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx17/THUMBNAIL/image/gif/1feb17e95f3a7e7ecf70f638977aca50/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14639</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>187</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx18/THUMBNAIL/image/gif/3ce6a2359176c545924c296cf0e5f298/fx18.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx18/THUMBNAIL/image/gif/3ce6a2359176c545924c296cf0e5f298/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10148</xocs:filesize>
               <xocs:pixel-height>95</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx2/THUMBNAIL/image/gif/a0f2dde44dd99429bbe4d71c196a67dc/fx2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx2/THUMBNAIL/image/gif/a0f2dde44dd99429bbe4d71c196a67dc/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10308</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx3/THUMBNAIL/image/gif/232b926fd45ba6215033ce1c4003dae4/fx3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx3/THUMBNAIL/image/gif/232b926fd45ba6215033ce1c4003dae4/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9774</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx4/THUMBNAIL/image/gif/39f37195d47bb108d9b3c85ae05c46b0/fx4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx4/THUMBNAIL/image/gif/39f37195d47bb108d9b3c85ae05c46b0/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12838</xocs:filesize>
               <xocs:pixel-height>152</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx5/THUMBNAIL/image/gif/a94f3a0ab3217d43ba003f2dde5026ee/fx5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx5/THUMBNAIL/image/gif/a94f3a0ab3217d43ba003f2dde5026ee/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8489</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx6/THUMBNAIL/image/gif/866cedcb148ba36dbc599b201b07b1e4/fx6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx6/THUMBNAIL/image/gif/866cedcb148ba36dbc599b201b07b1e4/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11399</xocs:filesize>
               <xocs:pixel-height>132</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx7/THUMBNAIL/image/gif/54be1c57b6636f2ad0551a5d7f8ffd43/fx7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx7/THUMBNAIL/image/gif/54be1c57b6636f2ad0551a5d7f8ffd43/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8160</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx8/THUMBNAIL/image/gif/b9a40cc8a144cf640e1a9cf21d876fb8/fx8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx8/THUMBNAIL/image/gif/b9a40cc8a144cf640e1a9cf21d876fb8/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11248</xocs:filesize>
               <xocs:pixel-height>93</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx9/THUMBNAIL/image/gif/c1270588dbbe925093e0eb9780fcfb49/fx9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx9/THUMBNAIL/image/gif/c1270588dbbe925093e0eb9780fcfb49/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14758</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr1/THUMBNAIL/image/gif/c4bc907d27c1f841ff26ca0a77d78cad/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr1/THUMBNAIL/image/gif/c4bc907d27c1f841ff26ca0a77d78cad/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>15070</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr2/THUMBNAIL/image/gif/deea3cce7ebbc644b403f76089dac448/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr2/THUMBNAIL/image/gif/deea3cce7ebbc644b403f76089dac448/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8792</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx1/DOWNSAMPLED/image/jpeg/8e733b2210e11e5bde1fd805356a062d/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx1/DOWNSAMPLED/image/jpeg/8e733b2210e11e5bde1fd805356a062d/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22305</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>310</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx10/DOWNSAMPLED/image/jpeg/0258fd77aa140bb8ecc282e68cd77e42/fx10.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx10/DOWNSAMPLED/image/jpeg/0258fd77aa140bb8ecc282e68cd77e42/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22836</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx11/DOWNSAMPLED/image/jpeg/8284fa4b626a17a2f098de016d90badc/fx11.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx11/DOWNSAMPLED/image/jpeg/8284fa4b626a17a2f098de016d90badc/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>28279</xocs:filesize>
               <xocs:pixel-height>205</xocs:pixel-height>
               <xocs:pixel-width>234</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx12/DOWNSAMPLED/image/jpeg/0f9fc39b6ff5d450f769899a86481729/fx12.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx12/DOWNSAMPLED/image/jpeg/0f9fc39b6ff5d450f769899a86481729/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27527</xocs:filesize>
               <xocs:pixel-height>186</xocs:pixel-height>
               <xocs:pixel-width>248</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx13/DOWNSAMPLED/image/jpeg/d31d71bdfcd9422315dd1731d852e6a9/fx13.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx13/DOWNSAMPLED/image/jpeg/d31d71bdfcd9422315dd1731d852e6a9/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23787</xocs:filesize>
               <xocs:pixel-height>132</xocs:pixel-height>
               <xocs:pixel-width>215</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx14/DOWNSAMPLED/image/jpeg/5a913acfb76c32f4721e4223eb55fdbe/fx14.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx14/DOWNSAMPLED/image/jpeg/5a913acfb76c32f4721e4223eb55fdbe/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40064</xocs:filesize>
               <xocs:pixel-height>193</xocs:pixel-height>
               <xocs:pixel-width>240</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx15/DOWNSAMPLED/image/jpeg/dba031afb87dc36dba2c17650c175c67/fx15.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx15/DOWNSAMPLED/image/jpeg/dba031afb87dc36dba2c17650c175c67/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>33122</xocs:filesize>
               <xocs:pixel-height>154</xocs:pixel-height>
               <xocs:pixel-width>222</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx16/DOWNSAMPLED/image/jpeg/5f634f28a17b954765952732fb548257/fx16.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx16/DOWNSAMPLED/image/jpeg/5f634f28a17b954765952732fb548257/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46499</xocs:filesize>
               <xocs:pixel-height>241</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx17/DOWNSAMPLED/image/jpeg/27cad8a7f153ecd118216dc368138bbe/fx17.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx17/DOWNSAMPLED/image/jpeg/27cad8a7f153ecd118216dc368138bbe/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>30821</xocs:filesize>
               <xocs:pixel-height>214</xocs:pixel-height>
               <xocs:pixel-width>244</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx18/DOWNSAMPLED/image/jpeg/471a014863393848c2551d89d4325019/fx18.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx18/DOWNSAMPLED/image/jpeg/471a014863393848c2551d89d4325019/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20538</xocs:filesize>
               <xocs:pixel-height>108</xocs:pixel-height>
               <xocs:pixel-width>249</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx2/DOWNSAMPLED/image/jpeg/6f587ea00424c32800a268d3b9626f1c/fx2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx2/DOWNSAMPLED/image/jpeg/6f587ea00424c32800a268d3b9626f1c/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21192</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>234</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx3/DOWNSAMPLED/image/jpeg/9bf37b4055355802d4c4a9e180fa100b/fx3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx3/DOWNSAMPLED/image/jpeg/9bf37b4055355802d4c4a9e180fa100b/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19369</xocs:filesize>
               <xocs:pixel-height>138</xocs:pixel-height>
               <xocs:pixel-width>245</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx4/DOWNSAMPLED/image/jpeg/395cb6db9a53a3444d411bc9c89ed892/fx4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx4/DOWNSAMPLED/image/jpeg/395cb6db9a53a3444d411bc9c89ed892/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26616</xocs:filesize>
               <xocs:pixel-height>167</xocs:pixel-height>
               <xocs:pixel-width>241</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx5/DOWNSAMPLED/image/jpeg/0554f79c9271896a6752b9e575bd08bc/fx5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx5/DOWNSAMPLED/image/jpeg/0554f79c9271896a6752b9e575bd08bc/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16886</xocs:filesize>
               <xocs:pixel-height>98</xocs:pixel-height>
               <xocs:pixel-width>251</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx6/DOWNSAMPLED/image/jpeg/cf9f877044bc3dc2e29bce8b13073577/fx6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx6/DOWNSAMPLED/image/jpeg/cf9f877044bc3dc2e29bce8b13073577/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21445</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>211</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx7/DOWNSAMPLED/image/jpeg/6e485e098eba9b495d9eeee70ffdbc3d/fx7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx7/DOWNSAMPLED/image/jpeg/6e485e098eba9b495d9eeee70ffdbc3d/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>16205</xocs:filesize>
               <xocs:pixel-height>109</xocs:pixel-height>
               <xocs:pixel-width>237</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx8/DOWNSAMPLED/image/jpeg/ba1c01f05798afcd59584ff3951b30b9/fx8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx8/DOWNSAMPLED/image/jpeg/ba1c01f05798afcd59584ff3951b30b9/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21049</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx9/DOWNSAMPLED/image/jpeg/91cb535a56478ea7697751c3281e5632/fx9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx9/DOWNSAMPLED/image/jpeg/91cb535a56478ea7697751c3281e5632/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27222</xocs:filesize>
               <xocs:pixel-height>171</xocs:pixel-height>
               <xocs:pixel-width>189</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr1/DOWNSAMPLED/image/jpeg/15ae5da893dbbfabdf134030be579bd7/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr1/DOWNSAMPLED/image/jpeg/15ae5da893dbbfabdf134030be579bd7/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>103686</xocs:filesize>
               <xocs:pixel-height>419</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr2/DOWNSAMPLED/image/jpeg/a05c9b6e73a09135591a4568f56fc0fc/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr2/DOWNSAMPLED/image/jpeg/a05c9b6e73a09135591a4568f56fc0fc/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>67424</xocs:filesize>
               <xocs:pixel-height>439</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx1/HIGHRES/image/jpeg/dca6675d929601b2b399d07342c2f9ea/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx1/HIGHRES/image/jpeg/dca6675d929601b2b399d07342c2f9ea/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>169086</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1376</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx10/HIGHRES/image/jpeg/9d82e633dc68ea10f25660db0bba3fd5/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx10/HIGHRES/image/jpeg/9d82e633dc68ea10f25660db0bba3fd5/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>69471</xocs:filesize>
               <xocs:pixel-height>669</xocs:pixel-height>
               <xocs:pixel-width>917</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx11/HIGHRES/image/jpeg/d5e1e7077b89014835718d9d9988dd72/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx11/HIGHRES/image/jpeg/d5e1e7077b89014835718d9d9988dd72/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>92596</xocs:filesize>
               <xocs:pixel-height>909</xocs:pixel-height>
               <xocs:pixel-width>1037</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx12/HIGHRES/image/jpeg/4edc25cbf64a997b7ef8302040412bfb/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx12/HIGHRES/image/jpeg/4edc25cbf64a997b7ef8302040412bfb/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>96751</xocs:filesize>
               <xocs:pixel-height>825</xocs:pixel-height>
               <xocs:pixel-width>1100</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx13/HIGHRES/image/jpeg/96db8ddc54e9db7639512c64c18b6a94/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx13/HIGHRES/image/jpeg/96db8ddc54e9db7639512c64c18b6a94/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>71749</xocs:filesize>
               <xocs:pixel-height>584</xocs:pixel-height>
               <xocs:pixel-width>952</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx14/HIGHRES/image/jpeg/127b821b4fdfaa27fffac49b24a86a7a/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx14/HIGHRES/image/jpeg/127b821b4fdfaa27fffac49b24a86a7a/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>128635</xocs:filesize>
               <xocs:pixel-height>857</xocs:pixel-height>
               <xocs:pixel-width>1064</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx15/HIGHRES/image/jpeg/990507954b1184a65afa2b103b1cd7ff/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx15/HIGHRES/image/jpeg/990507954b1184a65afa2b103b1cd7ff/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>91658</xocs:filesize>
               <xocs:pixel-height>682</xocs:pixel-height>
               <xocs:pixel-width>986</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx16/HIGHRES/image/jpeg/d0139662329513b2eadcf9894832fc49/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx16/HIGHRES/image/jpeg/d0139662329513b2eadcf9894832fc49/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>154691</xocs:filesize>
               <xocs:pixel-height>1068</xocs:pixel-height>
               <xocs:pixel-width>1113</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx17/HIGHRES/image/jpeg/97941115dbc2e393a8f46e1989acdf96/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx17/HIGHRES/image/jpeg/97941115dbc2e393a8f46e1989acdf96/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>105067</xocs:filesize>
               <xocs:pixel-height>952</xocs:pixel-height>
               <xocs:pixel-width>1084</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx18/HIGHRES/image/jpeg/9005d8165f9522c77506d2caa3868f82/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx18/HIGHRES/image/jpeg/9005d8165f9522c77506d2caa3868f82/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>59459</xocs:filesize>
               <xocs:pixel-height>476</xocs:pixel-height>
               <xocs:pixel-width>1102</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx2/HIGHRES/image/jpeg/f4987978ff2c2be452d0e2a47f77f92b/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx2/HIGHRES/image/jpeg/f4987978ff2c2be452d0e2a47f77f92b/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64860</xocs:filesize>
               <xocs:pixel-height>579</xocs:pixel-height>
               <xocs:pixel-width>1036</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx3/HIGHRES/image/jpeg/70a33cfa5cac73b8861d6bac9d79e3d5/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx3/HIGHRES/image/jpeg/70a33cfa5cac73b8861d6bac9d79e3d5/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>65014</xocs:filesize>
               <xocs:pixel-height>612</xocs:pixel-height>
               <xocs:pixel-width>1085</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx4/HIGHRES/image/jpeg/a52755a0c19043778c165d80f4dde268/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx4/HIGHRES/image/jpeg/a52755a0c19043778c165d80f4dde268/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>95559</xocs:filesize>
               <xocs:pixel-height>741</xocs:pixel-height>
               <xocs:pixel-width>1070</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx5/HIGHRES/image/jpeg/31f74c005c9c970c3fddfddd71e93e3c/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx5/HIGHRES/image/jpeg/31f74c005c9c970c3fddfddd71e93e3c/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53788</xocs:filesize>
               <xocs:pixel-height>433</xocs:pixel-height>
               <xocs:pixel-width>1114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx6/HIGHRES/image/jpeg/548ec7c67da746faa5ceafdfca628f41/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx6/HIGHRES/image/jpeg/548ec7c67da746faa5ceafdfca628f41/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>71884</xocs:filesize>
               <xocs:pixel-height>564</xocs:pixel-height>
               <xocs:pixel-width>937</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx7/HIGHRES/image/jpeg/aec13d0fbaf8d6208599ff41e51a0e98/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx7/HIGHRES/image/jpeg/aec13d0fbaf8d6208599ff41e51a0e98/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46794</xocs:filesize>
               <xocs:pixel-height>483</xocs:pixel-height>
               <xocs:pixel-width>1052</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx8/HIGHRES/image/jpeg/5a8169be2417a2014358ef942d755394/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx8/HIGHRES/image/jpeg/5a8169be2417a2014358ef942d755394/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>66599</xocs:filesize>
               <xocs:pixel-height>407</xocs:pixel-height>
               <xocs:pixel-width>958</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/fx9/HIGHRES/image/jpeg/7515b5bb616bd2a9b5f881f4976e4984/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/fx9/HIGHRES/image/jpeg/7515b5bb616bd2a9b5f881f4976e4984/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>79324</xocs:filesize>
               <xocs:pixel-height>760</xocs:pixel-height>
               <xocs:pixel-width>838</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr1/HIGHRES/image/jpeg/662dbfc0f10058bfa0287e06d43125dd/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr1/HIGHRES/image/jpeg/662dbfc0f10058bfa0287e06d43125dd/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>914923</xocs:filesize>
               <xocs:pixel-height>1856</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644614003559-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644614003559/gr2/HIGHRES/image/jpeg/a0a6cbec087197e3d0500880733ee1f0/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S1359644614003559/gr2/HIGHRES/image/jpeg/a0a6cbec087197e3d0500880733ee1f0/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>551921</xocs:filesize>
               <xocs:pixel-height>1943</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.2" xml:lang="en" docsubtype="rev">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>1492</aid>
            <ce:pii>S1359-6446(14)00355-9</ce:pii>
            <ce:doi>10.1016/j.drudis.2014.09.006</ce:doi>
            <ce:copyright type="full-transfer" year="2014">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0030" view="all">Molecular mode-of-action of microbial amphiphiles. <ce:bold>(a)</ce:bold> Lipopeptides inhibit various signaling pathways that are responsible for cancer development, proliferation, cell cycle progression, angiogenesis and inhibition of apoptosis. <ce:bold>(b)</ce:bold> α-Galactosylceramide (KRN7000), a sponge-derived glycolipid, shows anticancer action by activating natural killer T (NKT) cells.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0035" view="all">Cancer manifests as a result of accumulation of cellular and molecular transformations that ultimately lead to overexpression of several oncogenic pathways and suppression of apoptotic pathways such as phosphoinositide-3-kinase (PI3K)/Akt, Janus kinase/signal transducer and activator of transcription (JAK/STAT), mitogen-activated protein kinas (MAPK) and matrix metalloproteinase (MMP) pathways. Modulating these oncogenic and apoptotic pathways is a well established strategy for cancer therapy. Microbial amphiphiles are reported to possess anticancer activity through modulating these pathways.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0040" view="all">Structure of various amphiphile molecules and their structure–function relationships</ce:simple-para>
               </ce:caption>
               <tgroup cols="4">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <thead valign="top">
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Type of amphiphile</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Structure of amphiphile</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Structure–function relationship</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Biological effects and refs</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="8" rowsep="1" align="left">
                           <bold>Lipopeptides</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx2"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Ampiphilic structure and long-chain fatty acid interact with cell membrane. Glutamic acid in peptide chain is crucial for antimicrobial activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer and antimicrobial effects <cross-refs id="crfs0005" refid="bib0085 bib0205">[17,41]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Replacement of glutamic acid of surfactin with glutamine in hallobacilin displayed moderate anticancer activity but no antimicrobial activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer activity <cross-ref id="crf0005" refid="bib0205">[41]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Long and linear chain of fatty acid (mixirin A) showed more potent cytotoxicity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer effect on colon cancer <cross-ref id="crf0010" refid="bib0210">[42]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Interaction of fengycin with membrane lipids</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer and antifungal but not antibacterial <cross-refs id="crfs0010" refid="bib0025 bib0110">[5,22]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Disulfide bridge and dimeric configuration are required for cytotoxic action</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Potent anticancer action <cross-ref id="crf0015" refid="bib0030">[6]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lipophilic tail plays important part in cell cytotoxicity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer and nerve growth factor (NGF) stimulatory effects <cross-ref id="crf0020" refid="bib0115">[23]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pseudofactin-II causes loss of membrane integrity of cells</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Apoptotic effect in cancer cells <cross-ref id="crf0025" refid="bib0240">[48]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lipid chain is crucial for cytotoxic action and core macrocycle ring is important for <italic>in vitro</italic> anti-invasive actions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hypoxia-selective anticancer action <cross-ref id="crf0030" refid="bib0265">[53]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Methyl group at C(40) position is important for biological activity<br/></br>Replacement of thiazoline with oxazoline decreases cytotoxicity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Anticancer activity <cross-ref id="crf0035" refid="bib0120">[24]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="7" align="left">
                           <bold>Glycolipids</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Longer phenotype long chain base displays more-potent activity and 3-hydroxyl group is crucial for antitumor activity<br/></br>It activates natural killer T cells</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Antitumor effect and antimalarial effects in murine model <cross-ref id="crf0040" refid="bib0125">[25]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Fatty acid moiety as well sulfate group in monosaccharide are responsible for DNA polymerase inhibitory activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer action <cross-ref id="crf0045" refid="bib0105">[21]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lactone ring in fatty acid chain and formation of CMC contribute to cytotoxicity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Antiproliferative effect <cross-ref id="crf0050" refid="bib0130">[26]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">It perturbs the composition of membrane glycolipid GM3 and lactosylceramide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Induction of cell differentiation and apoptosis <cross-ref id="crf0055" refid="bib0135">[27]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Sophorolipids having one double bond in fatty acid chain promote the anticancer activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer action <cross-ref id="crf0060" refid="bib0140">[28]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Formation of critical micelle concentration (CMC) and even an odd number of carbon chain fatty acids attributed to biological action</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Apoptotic and cell differentiation effects <cross-ref id="crf0065" refid="bib0145">[29]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Peracetylation of myrmekioside E1 leads to formation of myrmekioside E2 and increases cell cytotoxicity<br/></br>But deacetylated form of myrmekioside E3 displays less cytotoxicity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer effect <cross-ref id="crf0070" refid="bib0350">[70]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Nature of sugar residue, double bond and lipophilic part play important part in biological activities</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Anticancer activity <cross-ref id="crf0075" refid="bib0350">[70]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0010" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0045" view="all">Effect of several lipopeptides on various cancer cell lines</ce:simple-para>
               </ce:caption>
               <tgroup cols="5">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <thead valign="top">
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Lipopeptide</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Cell line</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Type of cancer</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>IC</bold>
                           <inf loc="post">
                              <bold>50</bold>
                           </inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Refs</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" rowsep="1" align="left">
                           <bold>Surfactin</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24.8<hsp sp="0.25"/></hsp>mg/l</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" rowsep="1" align="left">
                           <cross-ref id="crf0080" refid="bib0100">[20]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">27.3<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" rowsep="1" align="left">
                           <bold>Fengycin</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HCT-15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human colon cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">80<hsp sp="0.25"/></hsp>μg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" rowsep="1" align="left">
                           <cross-ref id="crf0085" refid="bib0010">[2]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">HT-29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Human colon cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">120<hsp sp="0.25"/></hsp>μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="8" rowsep="1" align="left">
                           <bold>Somocystinamide A</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Jurkat</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="8" rowsep="1" align="left">
                           <cross-ref id="crf0090" refid="bib0015">[3]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CEM</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">14<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Lung carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">46<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Molt4 T cell</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">60<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">210<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NB7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Neuroblastoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">810<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PC3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prostate carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">970<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">M21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">U266</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Myeloma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">5.8<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" rowsep="1" align="left">
                           <bold>Fellutamide C</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33.1<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" rowsep="1" align="left">
                           <cross-ref id="crf0095" refid="bib0140">[28]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SK-OV-3 SK-MEL-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human ovarian cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.8<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">XF498</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human skin cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.1<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HCT-15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human CNS cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.9<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Human colon cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">3.1<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Fellutamide C</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">440<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" rowsep="1" align="left">
                           <cross-ref id="crf0100" refid="bib0145">[29]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Fellutamide D</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">PC-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Prostate cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">160<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" rowsep="1" align="left">
                           <bold>Fellutamide F</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.81<hsp sp="0.25"/></hsp>μg/ml</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" rowsep="1" align="left">
                           <cross-ref id="crf0105" refid="bib0150">[30]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SK-OV-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human ovarian cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.20<hsp sp="0.25"/></hsp>μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SK-MEL-2 XF498</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human skin cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.67<hsp sp="0.25"/></hsp>μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HCT-15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human CNS cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.14<hsp sp="0.25"/></hsp>μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Human colon cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">0.13<hsp sp="0.25"/></hsp>μg/ml</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Pseudofactin-II</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">A375 cells</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Melanoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left"><130<hsp sp="0.25"/></hsp>μ<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <cross-ref id="crf0110" refid="bib0155">[31]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Apratoxin A sulfoxide</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">NCI-H460</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Human lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">89.9<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <cross-ref id="crf0115" refid="bib0160">[32]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Apratoxin D</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">H-460</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">Human lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">2.6<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <cross-ref id="crf0120" refid="bib0165">[33]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Apratoxin H</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCI-H460</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Human lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.4<hsp sp="0.25"/></hsp>n<small-caps>m</small-caps>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0160">[32]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0015" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="spar0050" view="all">Clinical trials of a newly discovered biomolecules for different types of cancer</ce:simple-para>
               </ce:caption>
               <tgroup cols="4">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <thead valign="top">
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Nature and</bold> 
                           <italic>
                              <bold>modus operandi</bold>
                           </italic> 
                           <bold>of the study</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Cancer type</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Outcome with remarks</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" rowsep="1" align="left">
                           <bold>Refs</bold>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Phase I clinical trial of KRN7000-pulsed dendritic cells in cancer patients</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Non-small-cell lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">The findings indicated safety profile and tolerability in patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0130" refid="bib0245">[49]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Phase I study of KRN7000 in cancer patients</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Solid tumor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">KRN7000 was well tolerated as well as activation of antitumor immunity being detected in cancer patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0135" refid="bib0250">[50]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Phase I study of administration KRN7000-pulsed antigen-presenting cells (APCs) into cancer patients</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Head and neck squamous cell carcinoma (HNSCC)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Injection of KRN7000-pulsed APCs showed therapeutic efficacy in cancer patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0140" refid="bib0255">[51]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Phase I open-label clinical trial of cancer immunotherapy with KRN7000-pulsed dendritic cells in various cancer patients</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Metastatic malignancy</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">T cell activation, enhanced cytotoxicity of natural killer cells, increased serum interferon (IFN)-γ and interleukin (IL)-12 level, which are important for antitumor actions</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0145" refid="bib0260">[52]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>Combination therapy of natural killer T cells and KRN7000-pulsed APCs in cancer patients</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Head and neck carcinoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">The combination displayed antitumor activity and some beneficial clinical effects</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0150" refid="bib0265">[53]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Post screen</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">Microbial amphiphiles: a class of promising new-generation anticancer agents</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005">
                  <ce:given-name>Goutam</ce:given-name>
                  <ce:surname>Dey</ce:surname>
                  <ce:cross-ref id="crf0155" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0010">
                  <ce:given-name>Rashmi</ce:given-name>
                  <ce:surname>Bharti</ce:surname>
                  <ce:cross-ref id="crf0160" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0015">
                  <ce:given-name>Ramkrishna</ce:given-name>
                  <ce:surname>Sen</ce:surname>
                  <ce:cross-ref id="crf0165" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0170" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
                  
               </ce:author>
               <ce:author id="aut0020">
                  <ce:given-name>Mahitosh</ce:given-name>
                  <ce:surname>Mandal</ce:surname>
                  <ce:cross-ref id="crf0175" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0180" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005">
                  <ce:label>1</ce:label>
                  <ce:textfn>School of Medical Science & Technology, Indian Institute of Technology Kharagpur, India</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Medical Science & Technology, Indian Institute of Technology Kharagpur</sa:organization>
                     <sa:country>India</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:affiliation id="aff0010">
                  <ce:label>2</ce:label>
                  <ce:textfn>Department of Biotechnology, Indian Institute of Technology Kharagpur, India</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Biotechnology, Indian Institute of Technology Kharagpur</sa:organization>
                     <sa:country>India</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding authors</ce:italic>:</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:abstract id="abs0005" class="graphical" view="all">
               <ce:section-title id="sect0005">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abst0005" view="all">
                  <ce:simple-para id="spar0005" view="all"/></ce:simple-para>
               </ce:abstract-sec>
               <ce:figure id="fig0015">
                  <ce:link locator="fx1"/></ce:link>
               </ce:figure>
            </ce:abstract>
            
            <ce:abstract id="abs0015" view="all" class="author"><ce:abstract-sec id="abst0015" view="all">
                  <ce:simple-para id="spar0020" view="all">Developing new classes of anticancer molecules has always been a major scientific challenge owing to multidrug resistance of cancer cells to conventional chemotherapeutic agents. Microbial amphiphiles, particularly lipopeptides and glycolipids, have recently emerged as potential new-generation anticancer agents, owing to low toxicity, high efficacy and easy biodegradability. They exhibit anticancer activities by retarding cell cycle progression, inhibiting crucial signaling pathways such as Akt, extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) and Janus kinase/signal transducer and activator of transcription (JAK/STAT), reducing angiogenesis, activating natural killer T (NKT) cells and inducing apoptosis through death receptors in cancer cells. It has been well established that the oncogenic signals of cancer cells are amplified by the overexpression of various membrane-bound receptors such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and insulin-like growth factor receptor (IGFR). Microbial amphiphiles, upon interaction with the cell membrane, are believed to suppress the activities of these cell surface receptors by fatty acid chain mediated membrane destabilization. This review analyzes the modes and mechanisms of action of these green molecules for application as potential anticancer agents.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0015">Introduction</ce:section-title>
                  <ce:para id="par0025" view="all">Cancer is supposedly one of the greatest concerns for human health owing to the unpredictable nature of its causes and manifestation. The chemotherapeutic treatment options in practice are limited in terms of safety and efficacy, because of high toxicity and activation of several resistant pathways in cancer cells after a few days of exposure. Although the world has witnessed huge investments and sustained efforts in cancer research to develop anticancer drugs in the past few decades, remarkable success for a well-targeted selective therapy devoid of toxicity has not yet been achieved. This has necessitated a constant R&D drive to discover new effective and safe anticancer molecules. Some natural compounds of plant origin are already known for their use in cancer therapy such as taxol, vinca alkaloids and etoposides <ce:cross-ref id="crf0185" refid="bib0005">[1]</ce:cross-ref>. However, producing therapeutic molecules from plant sources does not seem to be an attractive business proposition because of the following reasons: (i) plants have relatively low growth rates; (ii) genetic engineering of plants is not as easy as bacteria; (iii) plants require large amounts of land and water. Therefore, resorting to microbes with relatively higher growth rates as sources for the anticancer molecules appears to be a more rational approach because they can be genetically modified with ease and they do not require much land or water. There are many reports on the production of anticancer therapeutics by bacteria. For example, actinomycin D and doxorubicin are produced by the soil bacteria <ce:italic>Streptomyces</ce:italic> sp. <ce:cross-refs id="crfs0015" refid="bib0010 bib0015">[2,3]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0030" view="all">Microbial amphiphiles are reported to possess tremendous commercial and therapeutic application potential <ce:cross-ref id="crf0190" refid="bib0020">[4]</ce:cross-ref>. The majority of the amphiphiles are extracellular secondary microbial metabolites that have been reported to have significant biological activities including antimicrobial, antifungal, antiviral and antimycoplasma <ce:cross-ref id="crf0195" refid="bib0020">[4]</ce:cross-ref>. These interesting molecules are also emerging as new-generation anticancer agents and drawing great attention from the global scientific community because of their high efficacy, biodegradability and low toxicity <ce:cross-refs id="crfs0020" refid="bib0020 bib0025 bib0030">[4–6]</ce:cross-refs>. Some lipopeptides, for example, somocystinamide A, rakicidin, apratoxin and fellutamides, are highly cytotoxic to different cancer cell lines as compared with conventional chemotherapeutic drugs.</ce:para>
                  <ce:para id="par0035" view="all">Deregulation and amplification of various signaling pathways such as phosphoinositide-3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK)/p38 c-Jun N-terminal kinase (JNK), cytokine-induced Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) and receptor tyrosin kinase (RTK) pathways generally lead to cancer formation and development of chemoresistance <ce:cross-refs id="crfs0025" refid="bib0035 bib0040">[7,8]</ce:cross-refs>. Inhibiting these pathways can be a molecular perspective for cancer therapy. Interestingly, many lipopeptides are also reported to interfere with these crucial signaling pathways <ce:cross-refs id="crfs0030" refid="bib0030 bib0045 bib0050">[6,9,10]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0040" view="all">Matrix metalloproteinases (MMPs) are a group of zinc- and calcium-dependent endopeptidase enzymes. Upregulation of MMP-2/9 has an essential role in cancer invasion and metastasis <ce:cross-ref id="crf0200" refid="bib0055">[11]</ce:cross-ref>. Secretion of this enzyme was inhibited by surfactin treatment in breast cancer cells suggesting its anti-invasive and antimetastatic properties <ce:cross-ref id="crf0205" refid="bib0055">[11]</ce:cross-ref>. So, microbial amphiphiles inhibiting these deregulated signaling pathways in cancer cells can be promising new molecules as anticancer agents. This article thus attempts to critically review the application potential of various microbial amphiphiles in cancer therapy, their mechanisms of action and bottlenecks in realizing their full potential as anticancer drugs and future directions.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0020">Types of amphiphiles and their anticancer properties</ce:section-title>
                  <ce:para id="par0045" view="all">Chemically, amphiphiles consist of hydrophobic saturated or unsaturated fatty acids and hydrophilic peptides or a polysaccharide. Amphiphiles are purified and characterized from culture media of various microorganisms. The commercial potential of these molecules has not yet been fully realized owing to poor yields and constraints regarding obtaining ultrapure product for therapeutic application <ce:cross-ref id="crf0210" refid="bib0060">[12]</ce:cross-ref>. However, the production yields of microbial a<ce:italic>mphiphiles</ce:italic> can be enhanced by media and process optimization <ce:cross-refs id="crfs0035" refid="bib0065 bib0070">[13,14]</ce:cross-refs>. Microbial amphiphiles can be produced using petroleum hydrocarbon, glucose, sucrose and glycerol as substrates <ce:cross-refs id="crfs0040" refid="bib0075 bib0080">[15,16]</ce:cross-refs>. Microbial amphiphiles include lipopeptides, phospholipids and glycolipids, as well as other types of molecules.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0025">Structure–function relation of microbial amphiphiles</ce:section-title>
                  <ce:para id="par0050" view="all">Microbial amphiphiles display significant surface and emulsifying activities. These molecules increase the surface area as well as reduce surface tension at the interface. They also partition at the interface between two different phases. In aqueous environments, amphiphiles form structured aggregates called micelles. The concentration at which micelles are formed is known as the critical micelle concentration (CMC), which is crucial for biological activity <ce:cross-ref id="crf0215" refid="bib0085">[17]</ce:cross-ref>. These molecules are represented by different types of molecules with diverse properties and biological functions. Microbial amphiphiles are believed to interact with the cell membrane and manifest various bioactive properties. They interact with many membrane macromolecules such as lipopolysaccharides <ce:cross-ref id="crf0220" refid="bib0090">[18]</ce:cross-ref>, phosphatidylserine <ce:cross-ref id="crf0225" refid="bib0095">[19]</ce:cross-ref> and other membrane components <ce:cross-ref id="crf0230" refid="bib0100">[20]</ce:cross-ref>. Structural features including fatty acid chain length, amino acid composition, functional groups and type of sugar moiety greatly influence the biological activity of amphiphiles. We have summarized a number of amphiphiles and there structure–function relations in <ce:cross-ref id="crf0235" refid="tbl0005">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0005"/></ce:float-anchor> 
                     <ce:cross-refs id="crfs0045" refid="bib0105 bib0110 bib0115 bib0120 bib0125 bib0130 bib0135 bib0140 bib0145">[21–29]</ce:cross-refs>.</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="sect0030">Lipopeptides</ce:section-title>
                  <ce:para id="par0055" view="all">Lipopeptides are complex molecules composed of lipid moieties connected to a peptide chain. Lipopeptides are reported to have significant biological activities such as antifungal, antibacterial, antiviral and antitumor activities <ce:cross-refs id="crfs0050" refid="bib0150 bib0155">[30,31]</ce:cross-refs>. Daptomycin and polymixin B are two microbial-derived lipopeptide antibiotics that are FDA-approved antimicrobial agents. Here, we discuss the anticancer properties and molecular mode of action of various lipopeptide molecules (<ce:cross-ref id="crf0240" refid="tbl0005">Table 1</ce:cross-ref>). Among the reported lipopeptides, surfactin, iturin and fengycin are well known biosurfactants.</ce:para>
                  <ce:section id="sec0025" view="all">
                     <ce:section-title id="sect0035">Surfactin</ce:section-title>
                     <ce:para id="par0060" view="all">Among the reported lipopeptides, surfactin has been the most extensively explored. It is produced from various strains of <ce:italic>Bacillus subtilis</ce:italic> during fermentation <ce:cross-ref id="crf0245" refid="bib0160">[32]</ce:cross-ref> and composed of seven amino acids and a lipid part. Surfactin is synthesized through a unique nonribosomal protein synthesis catalyzed by a multi-enzymatic complex called surfactin synthetase <ce:cross-ref id="crf0250" refid="bib0160">[32]</ce:cross-ref>. The biosynthesis of surfactin is encoded by the <ce:italic>Srf</ce:italic> operon containing four open reading frames that encode different enzymes <ce:cross-ref id="crf0255" refid="bib0160">[32]</ce:cross-ref>. The four enzymatic subunits of surfactin synthetase are SrfA, SrfB, SrfC and SrfD <ce:cross-refs id="crfs0055" refid="bib0160 bib0165">[32,33]</ce:cross-refs>. Among them, SrfD starts the surfactin initiation reaction <ce:cross-ref id="crf0260" refid="bib0165">[33]</ce:cross-ref>. Surfactin is a lipopeptide consisting of 3-hydroxy-13-methyl-tetra decanoic acid amidated to the N-terminal amine of a heptapeptide moiety with the carboxyl terminal end of the peptide being further esterified to the hydroxyl group of the fatty acid. Structural characteristics revealed the presence of a heptapeptide with a LLDLLDL chiral sequence linked, via a lactone bond, to a hydroxy fatty acid. The antitumor activity of surfactin has been associated with the hydrophobic nature of the fatty acid component that interacts with the acyl chain of membrane-bound phospholipid <ce:cross-ref id="crf0265" refid="bib0085">[17]</ce:cross-ref>. Simultaneously, its peptide moiety strongly interacts with the polar heads of the membrane lipids in cancer cells. Surfactin, having a longer fatty acid chain, penetrates more efficiently into the cancer cell membrane <ce:cross-ref id="crf0270" refid="bib0085">[17]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0065" view="all">A recent study has demonstrated the anti-invasive and antimetastatic actions of surfactin on MCF-7 breast cancer cells through inhibiting MMP-9 <ce:cross-ref id="crf0275" refid="bib0055">[11]</ce:cross-ref>. MMPs are the protease enzymes that promote tumor invasion and metastasis through degradation of matrix collagen. This lipopeptide also inhibited 12-<ce:italic>O</ce:italic>-tetradecanoylphorbol-13-acetate (TPA)-induced nuclear factor (NF)-κB and activator protein (AP)-1 activation and nuclear translocation <ce:cross-ref id="crf0280" refid="bib0055">[11]</ce:cross-ref>. Further, it caused sustained inhibition of PI3K/Akt and MAPK signaling pathways in MCF-7 cells. It also caused reduction of unsaturation of fatty acid composition in the cell membrane that leads to cell apoptosis in Bcap-37 breast cancer cells <ce:cross-ref id="crf0285" refid="bib0085">[17]</ce:cross-ref>. Surfactin purified from <ce:italic>Bacillus natto</ce:italic> was first reported to have antitumor effects on Ehrlich ascites carcinoma cells <ce:cross-ref id="crf0290" refid="bib0170">[34]</ce:cross-ref> and this lipopeptide purified from the TK-1 strain has been shown to inhibit MCF-7 human breast cancer cells in a dose- and time-dependent manner <ce:cross-ref id="crf0295" refid="bib0175">[35]</ce:cross-ref>. Interestingly, it was found to be nontoxic in the normal cell lines BRL (buffalo–rat liver) and HEK-293 (human embryonic kidney 293) at the same dose. According to the study by Cao <ce:italic>et al.</ce:italic> surfactin caused induction of apoptosis and cell cycle arrest at G<ce:inf loc="post">2</ce:inf>/M phase in MCF-7 breast cancer cells as a result of caspase-3 cleavage in MCF-7 cells <ce:cross-ref id="crf0300" refid="bib0175">[35]</ce:cross-ref>. This was further substantiated by using caspase inhibitors ZVAD-fmk and Z-DEVD-fmk that reversed the effect of surfactin-induced apoptosis in an MCF-7 cell line. Caspases are a cystein aspartic acid protease family of proteins. Sequential activation of caspases plays a crucial part in apoptosis events or programmed cell death <ce:cross-ref id="crf0305" refid="bib0040">[8]</ce:cross-ref>. They are responsible for proteolytic cleavage of many proteins like poly(ADP-ribose) polymerase (PARP) and caspase-activated DNase (CAD). Another study by the same group demonstrated that surfactin caused intracellular Ca<ce:sup loc="post">2+</ce:sup> accumulation which has a major role in induction of apoptosis in MCF-7 cells <ce:cross-ref id="crf0310" refid="bib0180">[36]</ce:cross-ref>. They also reported that surfactin caused changes in expression of various cell cycle regulatory proteins. p53 is a protein that induces apoptosis and cell cycle arrest via activating another protein: p21. Surfactin was reported to induce cell cycle arrest at G2/M phase by increasing expression of p53 and p21 and decreasing expression of cyclin B1 and p34<ce:sup loc="post">cdc2</ce:sup> 
                        <ce:cross-ref id="crf0315" refid="bib0180">[36]</ce:cross-ref> (<ce:cross-ref id="crf0320" refid="fig0005">Fig. 1</ce:cross-ref>a<ce:float-anchor refid="fig0005"/></ce:float-anchor>).</ce:para>
                     <ce:para id="par0070" view="all">Another study showed that surfactin induced apoptosis in MCF-7 cells via reactive oxygen species (ROS) generation <ce:cross-ref id="crf0325" refid="bib0045">[9]</ce:cross-ref>. Antioxidants such as <ce:italic>N</ce:italic>-acetylcysteine and catalase prevented surfactin-induced cell death. This phenomenon suggested that ROS generation was involved in surfactin-mediated apoptosis. In the same study, surfactin induced sustained inhibition of the phosphorylation of ERK1/2 and JNK but not p38 (<ce:cross-ref id="crf0330" refid="fig0005">Fig. 1</ce:cross-ref>a). Surfactin triggered the mitochondrial/caspase apoptotic pathway indicated by enhanced Bax: B cell lymphoma 2 (Bcl-2) expression ratio, loss of mitochondrial membrane potential, cytochrome c release and caspase cascade activation. These phenomena suggested that surfactin induced apoptosis through the ROS/JNK-mediated mitochondrial/caspase pathway.</ce:para>
                     <ce:para id="par0075" view="all">Another study reported the effect of surfactin on the proliferation of human colon carcinoma cell line LoVo <ce:cross-ref id="crf0335" refid="bib0185">[37]</ce:cross-ref>. It strongly blocked the proliferation of LoVo human colon cancer cells by inducing proapoptotic activity and arresting the cell cycle. The anticancer property of surfactin was due to DNA fragmentation, PARP cleavage, caspase-3 activation and altered expression of many proteins like p21<ce:sup loc="post">WAF1/Cip1</ce:sup>, p53, cyclin-dependent kinase (CDK)2 and cyclin E. The antiproliferative activity of surfactin was also mediated by inhibiting extracellular-related protein kinase (ERK) and PI3K/Akt <ce:cross-ref id="crf0340" refid="bib0185">[37]</ce:cross-ref>. <ce:italic>B. subtilis</ce:italic> CSY191 is a probiotic and produces surfactin that demonstrated dose-dependent inhibition of the growth of MCF-7 cancer cells <ce:cross-ref id="crf0345" refid="bib0190">[38]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0030" view="all">
                     <ce:section-title id="sect0040">Iturin</ce:section-title>
                     <ce:para id="par0080" view="all">Iturins (bacillomycins, iturin A/C and mycosubtilins) are a class of lipopeptide produced by different strains of <ce:italic>Bacillus</ce:italic> sp. <ce:cross-ref id="crf0350" refid="bib0195">[39]</ce:cross-ref>. These are amphiphilic molecules containing a cyclic peptide chain conjugated with β amino C13 to C17 aliphatic chain <ce:cross-ref id="crf0355" refid="bib0195">[39]</ce:cross-ref>. The peptide chain contains seven amino acids with the constant sequence of LDDLLDL configuration. Among them, <ce:small-caps>d</ce:small-caps>-Tyr at position 2 is an invariable amino acid <ce:cross-ref id="crf0360" refid="bib0200">[40]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0085" view="all">Hallobacilin is an iturin class of compound produced by <ce:italic>Bacillus</ce:italic> sp. derived from marine sediment near the Guaymas Basin, Mexico <ce:cross-ref id="crf0365" refid="bib0205">[41]</ce:cross-ref>. Hallobacilin is the first acylpeptide molecule of the iturin class from marine origin. It was reported to have cytotoxic activity on human colon cancer cell line HCT-116 with an IC<ce:inf loc="post">50</ce:inf> value of 0.98<ce:hsp sp="0.25"/></ce:hsp>μg/ml <ce:cross-ref id="crf0370" refid="bib0205">[41]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0090" view="all">Another iturin class of compounds, mixirins are cyclic octapeptides. They were isolated from a marine <ce:italic>Bacillus</ce:italic> sp. Mixirins are a mixture of <ce:small-caps>l</ce:small-caps>- and <ce:small-caps>d</ce:small-caps>-amino acid with an unusual β-amino alkanoic acid. The alkyl side-chains are different in different mixirins (mixirin A, B and C) (<ce:cross-ref id="crf0375" refid="tbl0005">Table 1</ce:cross-ref>). Mixirins are found to have anticancer effects and inhibit human colon cancer cell line HCT-116 <ce:cross-ref id="crf0380" refid="bib0210">[42]</ce:cross-ref>. Among them, mixirin A was found to be the most potent cytotoxic compound that has been ratified on HCT-116 colon cancer cells.</ce:para>
                  </ce:section>
                  <ce:section id="sec0035" view="all">
                     <ce:section-title id="sect0045">Fengycin</ce:section-title>
                     <ce:para id="par0095" view="all">Fengycin is a cyclic lipopeptide produced by <ce:italic>B. subtilis</ce:italic>. It comprises ten amino acids connected with a β-hydroxy fatty acid where eight amino acids are present in cyclic structure and two are in a linear structure. Sivapathasekaran <ce:italic>et al.</ce:italic> reported the cytotoxic activity of fengycin on human colon cancer cell lines HCT-15 and HT-29 <ce:cross-ref id="crf0385" refid="bib0025">[5]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0040" view="all">
                     <ce:section-title id="sect0050">Somocystinamide A</ce:section-title>
                     <ce:para id="par0100" view="all">Somocystinamide A is a potent antitumor lipopeptide with one disulphide bond. Biosynthetically it is produced as a secondary metabolite by a mixed enzymatic system: nonribosomal peptide synthetase (NRPS) and polyketide synthase (KPS) <ce:cross-ref id="crf0390" refid="bib0215">[43]</ce:cross-ref>. This highly acid-sensitive lipopeptide was purified from a cyanobacteria <ce:italic>Lyngbya majuscule</ce:italic>. Significant cytotoxic activity of somocystinamide A was found against mouse neuro-2a neuroblastoma cells. Later, the anticancer and antiangiogenic activities of this lipopeptide were demonstrated against leukemia, lung carcinoma, breast carcinoma and prostate carcinoma cell lines <ce:cross-ref id="crf0395" refid="bib0030">[6]</ce:cross-ref> (<ce:cross-ref id="crf0400" refid="tbl0010">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl0010"/></ce:float-anchor>). It induced apoptosis in Jurkat and leukemia cells through caspase-8 activation and PARP cleavage (<ce:cross-ref id="crf0405" refid="fig0005">Fig. 1</ce:cross-ref>a). The study conducted by Wrasidlo <ce:italic>et al.</ce:italic> 
                        <ce:cross-ref id="crf0410" refid="bib0030">[6]</ce:cross-ref> demonstrated whether somocystinamide A could induce apoptosis on wild-type and caspase-8-deficient Jurkat cells. It was found that caspase-8-deficient Jurkat cells were undergoing less apoptosis compared with wild-type cells indicating a selective role of caspase-8 in apoptosis induced by somocystinamide A. Further, it potently blocked endothelial cell tube formation <ce:italic>in vitro</ce:italic> and blood vessel growth in a zebrafish experiment demonstrating an antiangiogenic property of somocystinamide A.</ce:para>
                  </ce:section>
                  <ce:section id="sec0045" view="all">
                     <ce:section-title id="sect0055">Fellutamides</ce:section-title>
                     <ce:para id="par0105" view="all">This is a class of linear lipopeptides isolated from various fungi. Broad-spectrum biological activities like anti-inflammatory, antimalarial, antimicrobial, cytotoxic and neurotoxic activities of fellutamides have been reported <ce:cross-ref id="crf0415" refid="bib0220">[44]</ce:cross-ref>. Fellutamide A and fellutamide B were the first two lipopeptides isolated from the fish-derived fungus <ce:italic>Penicillium fellutanum</ce:italic>. Significant cytotoxic properties of these two lipopeptides on P388, L1210 murine leukemia cells and KB human epidermoid carcimoma cells have also been described <ce:cross-ref id="crf0420" refid="bib0225">[45]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0110" view="all">Another derivative fellutamide C displayed a cytotoxic effect on human SK-MEL-2 skin cancer, XF498 CNS cancer, HCT-15 colon cancer, A549 lung cancer and SK-OV-3 ovarian cancer cell lines <ce:cross-ref id="crf0425" refid="bib0230">[46]</ce:cross-ref>. The IC<ce:inf loc="post">50</ce:inf> values of these compounds are shown in <ce:cross-ref id="crf0430" refid="tbl0010">Table 2</ce:cross-ref>. Fellutamide C and D were isolated from <ce:italic>Metulocladosporiella</ce:italic>. These lipopeptides displayed anticancer effects of on PC-3 prostate cancer cells <ce:cross-ref id="crf0435" refid="bib0235">[47]</ce:cross-ref>. G2/M cell cycle arrest as well as apoptosis induced by these lipopeptides in PC-3 cells was confirmed by flow cytometry and caspase cascade activity. They were also reported to have versatile anticancer action against various cancer cell lines <ce:cross-ref id="crf0440" refid="bib0220">[44]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0050" view="all">
                     <ce:section-title id="sect0060">Pseudofactin</ce:section-title>
                     <ce:para id="par0115" view="all">Pseudofactin-I and pseudofactin-II are two novel cyclic lipopeptides isolated from arctic freshwater bacterium <ce:italic>Pseudomonas fluorescens</ce:italic> BD5 <ce:cross-ref id="crf0445" refid="bib0240">[48]</ce:cross-ref> (<ce:cross-ref id="crf0450" refid="tbl0005">Table 1</ce:cross-ref>). Pseudofactin-II demonstrated potent anticancer activity against melanoma A375 cells. Interestingly, it has no significant toxic effect on normal human dermal fibroblast (NHDF) and normal human epidermal keratinocyte (NHEK) cells <ce:cross-ref id="crf0455" refid="bib0240">[48]</ce:cross-ref>. This agent showed antiproliferative activity through inducing DNA fragmentation, caspase-3 activity, lactate dehydrogenase (LDH) release and Ca<ce:sup loc="post">2+</ce:sup> influx in melanoma A375 cells <ce:cross-ref id="crf0460" refid="bib0240">[48]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0055" view="all">
                     <ce:section-title id="sect0065">Rakicidin</ce:section-title>
                     <ce:para id="par0120" view="all">Marine bacteria <ce:italic>Micromonospora</ce:italic> produces antitumor lipopeptides rakicidin A and B <ce:cross-refs id="crfs0060" refid="bib0245 bib0250">[49,50]</ce:cross-refs>. Rakicidin A is a unique lipopeptide having hypoxia-selective cytotoxicity in many cancer cell lines <ce:cross-ref id="crf0465" refid="bib0255">[51]</ce:cross-ref>. The cytotoxic property of this lipopeptide was drastically high in hypoxic condition of HCT-8, PANC-1 and other cancer cells in comparison with normoxic conditions. This hypoxic condition presents mainly in solid tumors. It results in invasiveness, angiogenesis, vasculogenesis, metastasis and resistance to cell death along with poor prognosis and clinical outcome with conventional chemotherapy and radiotherapy <ce:cross-ref id="crf0470" refid="bib0260">[52]</ce:cross-ref>. So, it is necessary to develop new hypoxic-selective cytotoxic agents.</ce:para>
                     <ce:para id="par0125" view="all">According to a study conducted by Xie <ce:italic>et al.</ce:italic> rakicidin B inhibited a number of cancer cell lines such as esophageal squamous cell carcinoma cells (EC109), lung cancer cells (A549 and 95D), gastric cancer cells (SGC7901), uterine cervix cancer cells (HeLa) and hepatocellular carcinoma cells (HepG2) <ce:cross-ref id="crf0475" refid="bib0250">[50]</ce:cross-ref>. Various studies like DNA fragmentation, flow cytometry and colony formation assay confirmed apoptosis induction in EC109 cells treated with rakicidin B. It also induced activation of caspase-3, -7 and -9, suggesting a crucial role for mitochondria in lipopeptide-induced cell death. Further, MAPK and JNK/p38 signaling pathways were blocked by treatment with this lipopeptide (<ce:cross-ref id="crf0480" refid="fig0005">Fig. 1</ce:cross-ref>a).</ce:para>
                     <ce:para id="par0130" view="all">Other derivatives of these lipopeptides, rakicidin C and D contain short lipid chains compared with rakicidin A and B <ce:cross-ref id="crf0485" refid="bib0265">[53]</ce:cross-ref>. These two lipopeptides displayed no cytotoxic properties. It suggested that the longer lipid chain interacts with biological membranes as well as hampering cell proliferation. Interestingly, rakicidin D was found to have anti-invasive activity on aggressive breast cancer cells <ce:italic>in vitro</ce:italic> 
                        <ce:cross-ref id="crf0490" refid="bib0265">[53]</ce:cross-ref>. It indicates that the macrocyclic ring in the structure of this lipopeptide is also responsible for biological activity.</ce:para>
                  </ce:section>
                  <ce:section id="sec0060" view="all">
                     <ce:section-title id="sect0070">Apratoxin</ce:section-title>
                     <ce:para id="par0135" view="all">Apratoxins are a new group of cyclic lipopeptide (apratoxin A, D, E, F and G) isolated from different marine cyanobacterium <ce:cross-ref id="crf0495" refid="bib0270">[54]</ce:cross-ref> and are extremely potent cytotoxic compounds against various types of cancer cells. Apratoxin A induced apoptosis which was confirmed by caspase-3/7 assay <ce:cross-ref id="crf0500" refid="bib0050">[10]</ce:cross-ref>. The study also reported inhibition of the interleukin (IL)-6-induced signaling pathway in human bone osteosarcoma U2OS cells by this lipopeptide. Further, downstream proteins of the IL-6 pathway: gp130, P-JAK1 (Tyr1022/1023), P-JAK2 (Tyr1007/1008) and P-STAT3 (Tyr705), were inhibited by apratoxin A treatment (<ce:cross-ref id="crf0505" refid="fig0005">Fig. 1</ce:cross-ref>a). iTRAQ-based proteomic analysis by LC–MS/MS displayed downregulation of a number of proteins in lipopeptide-treated groups <ce:cross-ref id="crf0510" refid="bib0050">[10]</ce:cross-ref>. Most of these downregulated proteins are receptor proteins, membrane-bound proteins, protein disulfide isomerise (PDI)-related proteins and other proteins present on endoplasmic reticulum (ER). This study suggested that apratoxin A inhibited the secretory pathway by hampering co-translational translocation. Apratoxin A sulfoxide and apratoxin H are new analogs isolated from cyanobacterium <ce:italic>Moorea producens</ce:italic> 
                        <ce:cross-ref id="crf0515" refid="bib0275">[55]</ce:cross-ref>. Further, chemical configuration of these two agents was elucidated with chemical degradation, MS, NMR and CD spectroscopy analysis. The above two compounds exhibited potent cytotoxic action on human NCI-H460 lung cancer cells. Robertson <ce:italic>et al.</ce:italic> described total asymmetric synthesis of another cyanobacteria-derived lipopeptide: apratoxin D, which displayed highly significant cytotoxicity on human lung cancer H-460 cells <ce:cross-ref id="crf0520" refid="bib0280">[56]</ce:cross-ref>. Other lipopeptides, apratoxin F and G were also found to possess potent antitumor activity <ce:cross-ref id="crf0525" refid="bib0285">[57]</ce:cross-ref>. A further study reported the cytotoxic effect of apratoxin F and G on NCI-H460 lung cancer and HCT-116 colon cancer cells as well as in a mouse model <ce:cross-ref id="crf0530" refid="bib0285">[57]</ce:cross-ref>. Another novel apratoxin hybrid A/E showed enhanced antitumor activity on HCT-116 cells. This hybrid caused more-potent inhibition of cell viability and vascular endothelial growth factor (VEGF)-A secretion in HCT-116 cells with reduced toxicity profile in the HCT116 tumor-bearing <ce:italic>nu</ce:italic>/<ce:italic>nu</ce:italic> mouse model <ce:cross-ref id="crf0535" refid="bib0290">[58]</ce:cross-ref>. So, these highly potent lipopeptide molecules are promising agents for cancer therapy.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0065" view="all">
                  <ce:section-title id="sect0075">Glycolipids</ce:section-title>
                  <ce:para id="par0140" view="all">Glycolipds are complex amphiphilic molecules comprising lipid and one or more carbohydrate moieties. They can be classified as trehalose lipids, sophorolipids and rhamnolipids <ce:cross-ref id="crf0540" refid="bib0295">[59]</ce:cross-ref>. These are essential components of the cell membrane of plants as well as animals. Several gycolipids are reported to have anticancer activity against various cancer cell lines as well as in the mouse model (<ce:cross-ref id="crf0545" refid="tbl0005">Table 1</ce:cross-ref>).</ce:para>
                  <ce:para id="par0145" view="all">α-Galactosylceramide (KRN7000) is a kind of glycolipid compound composed of a sugar moiety connected to a fatty acid chain and a sphingosine base isolated from marine sponge (<ce:cross-ref id="crf0550" refid="tbl0005">Table 1</ce:cross-ref>). An antitumor effect of this glycolipid has been reported in many cancers like liver, lung, EL-4 lymphoma, colon 26 adenocarcinoma, EL-4T cell lymphoma and sarcoma <ce:cross-refs id="crfs0065" refid="bib0300 bib0305">[60,61]</ce:cross-refs>.</ce:para>
                  <ce:para id="par0150" view="all">The antitumor action of this glycolipid is due to the activation of invariant natural killer T (iNKT) cells and subsequent production of interferon (IFN)-γ, IL-4 and other cytokines dose dependently. iNKT cells are a subpopulation of cytotoxic T cells. The T cell receptor (TCR) of iNKT cells recognizes the CD1d-receptor–KRN7000 complex of antigen-presenting cells (APCs) (<ce:cross-ref id="crf0555" refid="fig0005">Fig. 1</ce:cross-ref>b) <ce:cross-ref id="crf0560" refid="bib0310">[62]</ce:cross-ref>. This ultimately causes release of various cytokines. KRN7000 was also found to have an inhibitory effect in advanced cancer patients with hepatitis B or C infection <ce:cross-ref id="crf0565" refid="bib0315">[63]</ce:cross-ref>. A number of clinical trials have been conducted to assess the efficacy and safety profile of this molecule <ce:cross-refs id="crfs0070" refid="bib0320 bib0325 bib0330 bib0335 bib0340">[64–68]</ce:cross-refs> (<ce:cross-ref id="crf0570" refid="tbl0015">Table 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl0015"/></ce:float-anchor>).</ce:para>
                  <ce:para id="par0155" view="all">Another glycolipd sulfoquinovosyl diacylglycerol (SQDG) was obtained from spinach (<ce:italic>Spinacia oleracea</ce:italic> L.). SQDG inhibited DNA polymerase α, δ and ɛ <ce:cross-ref id="crf0575" refid="bib0345">[69]</ce:cross-ref>. It also inhibited proliferation of human cervical carcinoma HeLa cells <ce:italic>in vivo</ce:italic> as well as <ce:italic>in vitro</ce:italic>. Marine sponge <ce:italic>Myrmekioderma dendyi</ce:italic> produces a different type of glycolipid: myrmekioside <ce:cross-ref id="crf0580" refid="bib0350">[70]</ce:cross-ref>. The various derivatives of this agent: myrmekioside E-1, myrmekioside E-2 and myrmekioside E-3, induced anticancer action on two human non-small-cell lung cancer cells (NSCLC-N6 and A549). Farokhi <ce:italic>et al</ce:italic>. further demonstrated a related glycolipid, trikentroside, isolated from sponge <ce:italic>Trikentrion</ce:italic> also inhibited proliferation of human non-small-cell lung cancer A549 cells <ce:cross-ref id="crf0585" refid="bib0350">[70]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0070" view="all">
                  <ce:section-title id="sect0080">Other glycolipids</ce:section-title>
                  <ce:para id="par0160" view="all">Mannosylerythritol lipids (MEL-A and MEL-B) are glycolipid amphiphile molecules that are well known biosurfactants produced by <ce:italic>Pseudozyma rugulosa</ce:italic> 
                     <ce:cross-ref id="crf0590" refid="bib0355">[71]</ce:cross-ref>. A number of other glycolipids like succinoyl trehalose lipids (STL-1 and STL-3), sophorolipids (SL) and polyol lipids (PL) were produced by <ce:italic>Rhodococcus erythropolis</ce:italic> SD-74, <ce:italic>Candida apicola</ce:italic> IMET 43747 and <ce:italic>Aurebasidium</ce:italic> sp. <ce:cross-ref id="crf0595" refid="bib0360">[72]</ce:cross-ref>, respectively. MEL-A, MEL-B, STL-1 and STL-3, SL and PL showed inhibition of growth and induction of cell differentiation in leukemia cell lines K562, HL-60 and basophilic leukocyte cell line KU812 <ce:cross-ref id="crf0600" refid="bib0360">[72]</ce:cross-ref>. A cell viability study of MEL-A and MEL-B also indicated inhibition of HL-60 leukemia cells in the concentration range 5–10<ce:hsp sp="0.25"/></ce:hsp>μ<ce:small-caps>m</ce:small-caps>. Further, MEL-A, MEL-B and PL induced granulocyte differentiation whereas SL, STL-1 and STL-3 induced monocytic differentiation.</ce:para>
                  <ce:para id="par0165" view="all">The molecular mode-of-action for anticancer properties of these glycolipids was due to inhibition of phospholipid activity and Ca<ce:sup loc="post">2+</ce:sup>-dependent protein kinase C (PKC) in HL-60 cells. MEL-A also inhibited phosphorylation of a 60<ce:hsp sp="0.25"/></ce:hsp>kDa protein (serine/threonine) in HL-60 cells and 55, 65, 95 and 135<ce:hsp sp="0.25"/></ce:hsp>kDa proteins (tyrosine) in K562 cells <ce:cross-ref id="crf0605" refid="bib0365">[73]</ce:cross-ref>. A further study reported that MEL-A caused antiproliferative action on mouse B16 melanoma cells through inducing DNA fragmentation, sub-G1 cell cycle arrest and apoptosis <ce:cross-ref id="crf0610" refid="bib0370">[74]</ce:cross-ref>.</ce:para>
                  <ce:para id="par0170" view="all">A new sophorolipid and its derivatives isolated from <ce:italic>Candida bombicola</ce:italic> displayed cytotoxicity against human pancreatic carcinoma cells (HPAC) <ce:cross-ref id="crf0615" refid="bib0375">[75]</ce:cross-ref>. Among several derivatives of sophorolipid, methyl ester derivative was found to be prominent and cytotoxic against HPAC cells.</ce:para>
               </ce:section>
               <ce:section id="sec0075" view="all">
                  <ce:section-title id="sect0085">Concluding remarks and future perspectives</ce:section-title>
                  <ce:para id="par0175" view="all">Microbial amphiphiles have come of an age through an evolution from powerful surface active agents to new-generation anticancer molecules. In our earlier review <ce:cross-ref id="crf0620" refid="bib0060">[12]</ce:cross-ref> on commercial application potentials of microbial amphiphiles, we critically analyzed and highlighted the status of their biosynthesis, use of recombinant microbes and process optimization techniques for their enhanced production, use of waste materials for cost-effective manufacture and possible steps that might lead toward their commercial production in the near future. In this review, the global R&D activities on the therapeutic application of these interesting amphiphilic biomolecules as potential anticancer agents have been critically assessed. The anticancer activities in terms of IC<ce:inf loc="post">50</ce:inf> values were found to be comparable with or superior to those of the standard chemotherapeutic drugs. Their modes and mechanisms of action at the molecular level were also deciphered to provide new insights. Like some synthetic drug molecules that are in clinical trials, lipopeptides have the capability of interrupting certain signaling pathways relevant to development of cancer and chemoresistance (e.g. PI3K/Akt, MAPK/p38 JNK, cytokine-induced JAK1/JAK2/STAT3 and RTK pathways; <ce:cross-ref id="crf0625" refid="fig0010">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig0010"/></ce:float-anchor>). However, these amphiphilic molecules need to be subjected to rigorous clinical and preclinical research to qualify as candidate drugs for cancer therapy. Thus, in this article, a conscious effort has been made to capture the current trends in cancer research with these molecules as new-generation cancer therapy.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0005" view="all">
               <ce:section-title id="sect0090">Acknowledgments</ce:section-title>
               <ce:para id="par0180" view="all">The authors thankfully acknowledge the financial support received from the <ce:grant-sponsor id="gs1" sponsor-id="http://dx.doi.org/10.13039/501100001851" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Ministry of Earth Sciences (MoES)</ce:grant-sponsor>, Government of India, for the project grant No: <ce:grant-number refid="gs1">MoES/16/48/09/RDEAS</ce:grant-number>. G.D. acknowledges CSIR, India, for his fellowship. R.B. acknowledges IIT Kharagpur, India, for her institute fellowship.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0095">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Cragg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Newman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Plants as a source of anti-cancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Ethnopharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>72</sb:first-page>
                              <sb:last-page>79</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Hollstei</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Actinomycin – chemistry and mechanism of action</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:date>1974</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>625</sb:first-page>
                              <sb:last-page>652</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Niraula</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biotechnological doxorubicin production: pathway and regulation engineering of strains for enhanced production</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Appl. Microbiol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1187</sb:first-page>
                              <sb:last-page>1194</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Gudina</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential therapeutic applications of biosurfactants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>667</sb:first-page>
                              <sb:last-page>675</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Marine bacterium derived lipopeptides: characterization and cytotoxic activity against cancer cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Pept. Res. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>215</sb:first-page>
                              <sb:last-page>222</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wrasidlo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>105</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2313</sb:first-page>
                              <sb:last-page>2318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Das</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antineoplastic and apoptotic potential of traditional medicines thymoquinone and diosgenin in squamous cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS ONE</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e46641</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rajput</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLOS ONE</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e61342</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surfactin induces apoptosis in human breast cancer MCF-7 cells through a ROS/JNK-mediated mitochondrial/caspase pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Interact.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>183</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>357</sb:first-page>
                              <sb:last-page>362</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>91</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surfactin suppresses TPA-induced breast cancer cell invasion through the inhibition of MMP-9 expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>42</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>287</sb:first-page>
                              <sb:last-page>296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mukherjee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Towards commercial production of microbial surfactants</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>509</sb:first-page>
                              <sb:last-page>515</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Artificial neural network modeling and genetic algorithm based medium optimization for the improved production of marine biosurfactant</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioresour. Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2884</sb:first-page>
                              <sb:last-page>2887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Performance evaluation of an ANN-GA aided experimental modeling and optimization procedure for enhanced synthesis of marine biosurfactant in a stirred tank reactor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Technol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>794</sb:first-page>
                              <sb:last-page>799</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Rangarajan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Time-dependent dosing of Fe<ce:sup loc="post">2+</ce:sup> for improved lipopeptide production by marine <ce:italic>Bacillus megaterium</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Technol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1661</sb:first-page>
                              <sb:last-page>1669</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Performance evaluation of batch and unsteady state fed-batch reactor operations for the production of a marine microbial surfactant</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Technol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>719</sb:first-page>
                              <sb:last-page>726</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of the microbial lipopeptide on tumor cell lines: apoptosis induced by disturbing the fatty acid composition of cell membrane</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Protein Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>584</sb:first-page>
                              <sb:last-page>594</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Hwang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lipopolysaccharide-binding and neutralizing activities of surfactin C in experimental models of septic shock</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>556</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>166</sb:first-page>
                              <sb:last-page>171</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ortiz</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interactions of a bacterial biosurfactant trehalose lipid with phosphatidylserine membranes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Phys. Lipids</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>158</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>46</sb:first-page>
                              <sb:last-page>53</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Magetdana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ptak</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interactions of surfactin with membrane models</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biophys. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>68</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1937</sb:first-page>
                              <sb:last-page>1943</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gonzalez-Aseguinolaza</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8461</sb:first-page>
                              <sb:last-page>8466</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Vanittanakom</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fengycin – a novel antifungal lipopeptide antibiotic produced by <ce:italic>Bacillus subtilis</ce:italic> F-29-3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Antibiot.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>39</sb:volume-nr>
                              </sb:series>
                              <sb:date>1986</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>888</sb:first-page>
                              <sb:last-page>901</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Schneekloth</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Neurotrophic peptide aldehydes: solid phase synthesis of fellutamide B and a simplified analog</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3855</sb:first-page>
                              <sb:last-page>3858</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7615</sb:first-page>
                              <sb:last-page>7626</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Morita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure–activity relationship of α-galactosylceramides against B16-bearing mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2176</sb:first-page>
                              <sb:last-page>2187</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Isoda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakahara</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antiproliferative effect of polyol lipids, 3,5-dihydroxydecanoyl and 5-hydroxy-2-decenoyl esters of arabitol and mannitol on lung cancer cell line A549</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Ferment. Bioeng.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>84</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>403</sb:first-page>
                              <sb:last-page>406</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinase Cα plays a critical role in mannosylerythritol lipid-induced differentiation of melanoma B16 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39903</sb:first-page>
                              <sb:last-page>39910</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bioactivities of sophorolipid with different structures against human esophageal cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Surg. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>173</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>286</sb:first-page>
                              <sb:last-page>291</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sudo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Induction of the differentiation of human HL-60 promyelocytic leukemia cell line by succinoyl trehalose lipids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytotechnology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>259</sb:first-page>
                              <sb:last-page>264</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Matrix assisted laser desorption ionization-time of flight mass spectral analysis of marine lipopeptides with potential therapeutic implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Pept. Res. Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>79</sb:first-page>
                              <sb:last-page>85</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sivapathasekaran</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High-performance liquid chromatography purification of biosurfactant isoforms produced by a marine bacterium</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anal. Bioanal. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>395</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>845</sb:first-page>
                              <sb:last-page>854</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surfactin: biosynthesis, genetics and potential applications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biosurfactants</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>672</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>316</sb:first-page>
                              <sb:last-page>323</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Steller</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Initiation of surfactin biosynthesis and the role of the SrfD-thioesterase protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochemistry</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>11331</sb:first-page>
                              <sb:last-page>11343</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kameda</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor activity of <ce:italic>Bacillus natto</ce:italic>. V. Isolation and characterization of surfactin in the culture medium of <ce:italic>Bacillus natto</ce:italic> KMD 2311</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>1974</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>938</sb:first-page>
                              <sb:last-page>944</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Purification and antitumour activity of a lipopeptide biosurfactant produced by <ce:italic>Bacillus natto</ce:italic> TK-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biotechnol. Appl. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>106</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surfactin induces apoptosis and G(2)/M arrest in human breast cancer MCF-7 cells through cell cycle factor regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Biochem. Biophys.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>163</sb:first-page>
                              <sb:last-page>171</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Surfactin from <ce:italic>Bacillus subtilis</ce:italic> displays anti-proliferative effect via apoptosis induction, cell cycle arrest and survival signaling suppression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>581</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>865</sb:first-page>
                              <sb:last-page>871</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The production of surfactin during the fermentation of cheonggukjang by potential probiotic <ce:italic>Bacillus subtilis</ce:italic> CSY191 and the resultant growth suppression of MCF-7 human breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Food Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1347</sb:first-page>
                              <sb:last-page>1354</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.Y.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Production of iturin A by <ce:italic>Bacillus amyloliquefaciens</ce:italic> suppressing <ce:italic>Rhizoctonia solani</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Soil Biol. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>955</sb:first-page>
                              <sb:last-page>963</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.N.</ce:given-name>
                                 <ce:surname>Nasir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Besson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Conformational analyses of bacillomycin D, a natural antimicrobial lipopeptide, alone or in interaction with lipid monolayers at the air–water interface</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Colloid Interface Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>387</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>187</sb:first-page>
                              <sb:last-page>193</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Trischman</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Halobacillin – a cytotoxic cyclic acylpeptide of the iturin class produced by a marine <ce:italic>Bacillus</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5571</sb:first-page>
                              <sb:last-page>5574</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three new cytotoxic cyclic acylpeptides from marine <ce:italic>Bacillus</ce:italic> sp.</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1029</sb:first-page>
                              <sb:last-page>1030</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Suyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Gerwick</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stereospecific total synthesis of somocystinamide A</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4449</sb:first-page>
                              <sb:last-page>4452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A cytotoxic fellutamide analogue from the sponge-derived fungus <ce:italic>Aspergillus versicolor</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull. Korean Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3817</sb:first-page>
                              <sb:last-page>3820</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shigemori</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fellutamide-A and fellutamide-B, cytotoxic peptides from a marine fish-possessing fungus <ce:italic>Penicillium fellutanum</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8529</sb:first-page>
                              <sb:last-page>8534</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A cytotoxic lipopeptide from the sponge-derived fungus <ce:italic>Aspergillus versicolor</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull. Korean Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>205</sb:first-page>
                              <sb:last-page>208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Isolation, structure, and biological activities of fellutamides C and D from an undescribed <ce:italic>Metulocladosporiella</ce:italic> (<ce:italic>Chaetothyriales</ce:italic>) using the genome-wide <ce:italic>Candida albicans</ce:italic> fitness test</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Nat. Prod.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1721</sb:first-page>
                              <sb:last-page>1730</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Janek</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Lipopeptide biosurfactant pseudofactin II induced apoptosis of melanoma A 375 cells by specific interaction with the plasma membrane</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLOS ONE</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e57991</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.I.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>591</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FW523-3, a novel lipopeptide compound, induces apoptosis in cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Med. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>759</sb:first-page>
                              <sb:last-page>763</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yamazaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rakicidin A: a hypoxia-selective cytotoxin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biol. Pharm. Bull.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Wilson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Hay</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting hypoxia in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                              <sb:last-page>410</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.B.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A concise route to the macrocyclic core of the rakicidins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Commun.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12837</sb:first-page>
                              <sb:last-page>12839</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Nunnery</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biologically active secondary metabolites from marine cyanobacteria</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>787</sb:first-page>
                              <sb:last-page>793</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Thornburg</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apratoxin H and apratoxin A sulfoxide from the Red Sea cyanobacterium <ce:italic>Moorea producens</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Nat. Prod.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1781</sb:first-page>
                              <sb:last-page>1788</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Robertson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Asymmetric total synthesis of apratoxin D</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Org. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5192</sb:first-page>
                              <sb:last-page>5195</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tidgewell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evolved diversification of a modular natural product pathway: apratoxins F and G, two cytotoxic cyclic depsipeptides from a Palmyra collection of <ce:italic>Lyngbya bouillonii</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ChemBioChem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1458</sb:first-page>
                              <sb:last-page>1466</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Systematic chemical mutagenesis identifies a potent novel apratoxin A/E hybrid with improved <ce:italic>in vivo</ce:italic> antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>861</sb:first-page>
                              <sb:last-page>865</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.G.K.</ce:given-name>
                                 <ce:surname>Karanth</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Microbial production of biosurfactants and their importance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>116</sb:first-page>
                              <sb:last-page>126</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fuji</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3380</sb:first-page>
                              <sb:last-page>3387</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nakui</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Exp. Metastasis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>147</sb:first-page>
                              <sb:last-page>153</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hayakawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1720</sb:first-page>
                              <sb:last-page>1727</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.L.</ce:given-name>
                                 <ce:surname>Schneiders</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Clinical experience with alpha-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>140</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>130</sb:first-page>
                              <sb:last-page>141</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1910</sb:first-page>
                              <sb:last-page>1917</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Giaccone</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3702</sb:first-page>
                              <sb:last-page>3709</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamasaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>255</sb:first-page>
                              <sb:last-page>265</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nieda</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic activation of Vα24<ce:hsp sp="0.25"/></ce:hsp>+<ce:hsp sp="0.25"/></ce:hsp>Vβ11<ce:hsp sp="0.25"/></ce:hsp>+<ce:hsp sp="0.25"/></ce:hsp>NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>383</sb:first-page>
                              <sb:last-page>389</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kunii</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Combination therapy of <ce:italic>in vitro</ce:italic>-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1092</sb:first-page>
                              <sb:last-page>1098</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Maeda</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-tumor effects of the glycolipids fraction from spinach which inhibited DNA polymerase activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nutr. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>216</sb:first-page>
                              <sb:last-page>223</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Farokhi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antiproliferative activity against human non-small cell lung cancer of two <ce:italic>O</ce:italic>-alkyl-diglycosylglycerols from the marine sponges <ce:italic>Myrmekioderrna dendyi</ce:italic> and <ce:italic>Trikentrion laeve</ce:italic>
                              </sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>406</sb:first-page>
                              <sb:last-page>410</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0355">
                     <ce:label>71</ce:label>
                     <sb:reference id="sbref0355">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Morita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of <ce:italic>Pseudozyma rugulosa</ce:italic> NBRC 10877 as a novel producer of the glycolipid biosurfactants, mannosylerythritol lipids, based on rDNA sequence</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Appl. Microbiol. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>305</sb:first-page>
                              <sb:last-page>313</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0360">
                     <ce:label>72</ce:label>
                     <sb:reference id="sbref0360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kitamoto</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Functions and potential applications of glycolipid biosurfactants – from energy-saving materials to gene delivery carriers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biosci. Bioeng.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>187</sb:first-page>
                              <sb:last-page>201</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0365">
                     <ce:label>73</ce:label>
                     <sb:reference id="sbref0365">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Isoda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakahara</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mannosylerythritol lipid induces granulocytic differentiation and inhibits the tyrosine phosphorylation of human myelogenous leukemia cell line K562</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytotechnology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>191</sb:first-page>
                              <sb:last-page>195</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0370">
                     <ce:label>74</ce:label>
                     <sb:reference id="sbref0370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mannosylerythritol lipid is a potent inducer of apoptosis and differentiation of mouse melanoma cells in culture</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>482</sb:first-page>
                              <sb:last-page>486</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0375">
                     <ce:label>75</ce:label>
                     <sb:reference id="sbref0375">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sophorolipids and their derivatives are lethal against human pancreatic cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Surg. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>148</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>77</sb:first-page>
                              <sb:last-page>82</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>